NASDAQ:AKRX - Akorn Stock Price, Forecast & News

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn, Inc. (NASDAQ:AKRX) released its quarterly earnings data on Thursday, October, 31st. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.06. The business had revenue of $176.24 million for the quarter, compared to the consensus estimate of $176.15 million. Akorn had a negative net margin of 53.62% and a negative return on equity of 19.95%. The business's revenue for the quarter was up 6.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.06) EPS. View Akorn's Earnings History.

3 equities research analysts have issued twelve-month price targets for Akorn's stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate Akorn's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 293.5% from the stock's current price. View Analyst Price Targets for Akorn.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Akorn.

Media headlines about AKRX stock have trended extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akorn earned a news impact score of -4.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Akorn.

Akorn saw a decline in short interest in January. As of January 15th, there was short interest totalling 5,820,000 shares, a decline of 31.6% from the December 31st total of 8,510,000 shares. Based on an average trading volume of 2,360,000 shares, the short-interest ratio is presently 2.5 days. Approximately 6.1% of the shares of the company are sold short. View Akorn's Current Options Chain.

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Akorn's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (8.38%), Canyon Capital Advisors LLC (3.96%), State Street Corp (2.67%), Geode Capital Management LLC (1.51%), Connor Clark & Lunn Investment Management Ltd. (1.03%) and Maverick Capital Ltd. (0.98%). Company insiders that own Akorn stock include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.

AKRX stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Spark Investment Management LLC, Assenagon Asset Management S.A., Connor Clark & Lunn Investment Management Ltd., UBS Group AG and Bank of America Corp DE. View Insider Buying and Selling for Akorn.

AKRX stock was acquired by a variety of institutional investors in the last quarter, including Canyon Capital Advisors LLC, Maverick Capital Ltd., Renaissance Technologies LLC, Marshall Wace LLP, Marshall Wace North America L.P., Geode Capital Management LLC, Oxford Asset Management LLP and Gabelli Funds LLC. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKRX stock can currently be purchased for approximately $1.44.

Akorn has a market capitalization of $181.66 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.

The official website for Akorn is http://www.akorn.com/.

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]